Overview

Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.

Status:
Recruiting
Trial end date:
2023-08-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of secukinumab in Chinese participants with active PsA compared to placebo
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antibodies, Monoclonal